Apoptotic cells trigger a membrane-initiated pathway to increase ABCA1

Aaron M. Fond,1,2 Chang Sup Lee,1,2 Ira G. Schulman,3 Robert S. Kiss,4,5 and Kodi S. Ravichandran1,2
1The Center for Cell Clearance, 2Department of Microbiology, Immunology, and Cancer Biology, and 3Department of Pharmacology, University of Virginia (UVA), Charlottesville, Virginia, USA.
4Department of Medicine, McGill University, Montreal, Quebec, Canada. 5Research Institute of McGill University Health Centre, Montreal, Quebec, Canada.

Macrophages clear millions of apoptotic cells daily and, during this process, take up large quantities of cholesterol. The membrane transporter ABCA1 is a key player in cholesterol efflux from macrophages and has been shown via human genetic studies to provide protection against cardiovascular disease. How the apoptotic cell clearance process is linked to macrophage ABCA1 expression is not known. Here, we identified a plasma membrane–initiated signaling pathway that drives a rapid upregulation of ABCA1 mRNA and protein. This pathway involves the phagocytic receptor brain-specific angiogenesis inhibitor 1 (BAI1), which recognizes phosphatidylserine on apoptotic cells, and the intracellular signaling intermediates engulfment cell motility 1 (ELMO1) and Rac1, as ABCA1 induction was attenuated in primary macrophages from mice lacking these molecules. Moreover, this apoptotic cell–initiated pathway functioned independently of the liver X receptor (LXR) sterol–sensing machinery that is known to regulate ABCA1 expression and cholesterol efflux. When placed on a high-fat diet, mice lacking BAI1 had increased numbers of apoptotic cells in their aortic roots, which correlated with altered lipid profiles. In contrast, macrophages from engineered mice with transgenic BAI1 overexpression showed greater ABCA1 induction in response to apoptotic cells compared with those from control animals. Collectively, these data identify a membrane-initiated pathway that is triggered by apoptotic cells to enhance ABCA1 within engulfing phagocytes and with functional consequences in vivo.

Introduction
A majority of the approximately 200 billion cells turned over daily as part of normal homeostasis in various tissues of our body die via apoptosis (1–3). These dying cells are subsequently cleared by professional phagocytes (such as macrophages) and by nonprofessional neighboring cells (such as epithelial cells). When a phagocyte ingests an apoptotic cell, it increases its cellular contents and metabolic load. Since macrophages can often engulf multiple apoptotic cells, processing of the ingested contents has important implications for many metabolic disorders (4, 5). Most cells, including macrophages, lack the capacity to break down cholesterol, one of the major apoptotic cell–derived components, thus making the efflux of cellular-free cholesterol critical for lipid homeostasis (6–9).

Macrophages actively export their cellular cholesterol via ABC transporters, with ABCA1 and ABCG1 being the best studied (10–13). ABCA1 exports cellular phospholipids and cholesterol to lipid-poor apolipoprotein A1 (ApoA1), which is critical for the biogenesis of HDL (14); on the other hand, ABCG1 transfers cholesterol primarily to lipid-rich HDL (15). These HDL moieties are then taken up by the liver and excreted through the bile, a process termed “reverse cholesterol transport,” which is a major mechanism for lowering the cholesterol load in cells throughout the body (16).

Atherosclerosis, which can progress to cardiovascular disease, has been a leading cause of death in the United States for almost a century (17). While the etiology of atherosclerosis is complex, macrophages play a key role in the development of atherosclerotic plaques in the vessel wall and the perpetuation of inflammation within the lesions (18–22). In humans and mice, multiple studies have shown that higher levels of ABCA1 and higher HDL correlate with reduced risk for cardiovascular disease (23–25). Patients with genetic ABCA1 deficiencies show severe dyslipidemia (26). It has also been reported that HDL generated by ABCA1 can have beneficial antiinflammatory effects in different tissues (27). Therefore, defining the modalities by which ABCA1 levels are regulated in physiological settings becomes important.

Previously, using macrophage cell lines in vitro, we observed that apoptotic cells induce cholesterol efflux, which was linked to higher levels of ABCA1 protein expression induced in the phagocytes (28). This induction of cholesterol efflux by the macrophages was found to be dependent on the recognition of phosphatidylserine (PtdSer), a key eat-me signal on the apoptotic cells, by the phagocytes (28). However, how the PtdSer recognition triggers ABCA1 in phagocytes and the in vivo relevance of this apoptotic cell–induced ABCA1 induction is not known. Here, using primary macrophages, we identify a membrane-initiated pathway by which recognition of apoptotic cells triggers ABCA1 upregulation in phagocytes. Using gain-of-function and loss-of-function mouse models, we show that the membrane receptor brain-specific angiogenesis inhibitor 1 (BAI1), along with its cytoplasmic intermediaries engulfment cell motility 1 (ELMO1) and Rac1, represents a new signaling pathway to induce ABCA1 under physiological conditions.
recognition also occurs in primary resident peritoneal macrophages and in an in vivo context. We injected apoptotic cells into the peritoneum of WT mice and assessed ABCA1 in the cells recovered from the peritoneal lavage. As murine macrophages can recognize and engulf apoptotic cells of human or murine origin.

**Results**

Apoptotic cells induce a transcriptional upregulation of ABCA1. Due to the reported differences in cholesterol homeostasis between macrophage cell lines and primary macrophages (29), we first asked whether the upregulation of ABCA1 during apoptotic cell recognition also occurs in primary resident peritoneal macrophages and in an in vivo context. We injected apoptotic cells into the peritoneum of WT mice and assessed ABCA1 in the cells recovered from the peritoneal lavage. As murine macrophages can recognize and engulf apoptotic cells of human or murine origin.
upregulation was assessed in a time course (2 independent experiments, mean ± SD). Peritoneal macrophages were incubated with surrogate targets (carboxylate-modified latex beads), and the upregulation of Abca1 was assessed in a time course.  

Figure 2. Primary resident peritoneal macrophages rapidly upregulate Abca1 in response to apoptotic cell recognition. (A) Abca1 mRNA levels from primary peritoneal macrophages treated with vehicle control, 1 μM cytochalasin D, or 5 μg/ml actinomycin D, and incubated with apoptotic Jurkat cells (2 hours) (mean ± SD). Representative of 3 independent experiments. *P < 0.05 (2-way ANOVA, Bonferroni’s post tests comparing control treated to apoptotic cell treated).  

(B) Primary peritoneal macrophages were left untreated, treated with 2 × 10^6 apoptotic Jurkat (AJ) cells, or treated with 2 × 10^6 apoptotic Jurkat cells that had been treated with MJCD (AJ-MJCD). Macrophages were treated for 2 hours before RNA was isolated. Representative of 2 independent experiments. (C) Peritoneal macrophages were incubated with surrogate targets (carboxylate-modified latex beads), and the upregulation of Abca1 upregulation was assessed in a time course (2 independent experiments, mean ± SD).

As we assessed the upregulation of murine ABCA1 in the phagocytes. Four hours after intraperitoneal apoptotic cell injection, the cells isolated from the peritoneal lavage showed nearly 5-fold upregulation of murine Abca1 mRNA (Figure 1A). When we analyzed ABCA1 surface levels by flow cytometry 6 hours after intraperitoneal injection of apoptotic thymocytes or vehicle control, we found that peritoneal macrophages (IgM−, CD11b+) increased their ABCA1 surface levels, whereas B cells (IgM+) had no change in ABCA1 levels (Figure 1B). To further characterize the effects of apoptotic cell treatment on ABCA1 levels in resident peritoneal macrophages, we cultured peritoneal lavage cells for 3 days, at which time 90% of the remaining cells were macrophages (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI83000DS1). Cultured primary peritoneal macrophages incubated with apoptotic cells demonstrated a rapid upregulation of ABCA1 in as little as 2 hours in response to apoptotic cells. The higher Abca1 levels induced by apoptotic cells remained for many hours; under the same conditions, Abcg1 and Cd36, two other genes regulated by sterol sensing, were largely unaffected (Figure 1C). The increase in Abca1 transcript levels corresponded with greater surface expression of ABCA1 protein in macrophages (Figure 1, D and E). Furthermore, there was an increase in cholesterol efflux to ApoA1, a measure of ABCA1 function (Figure 1F). These data suggested that apoptotic cells induce Abca1 mRNA and protein in primary macrophages.

We initially considered that sensing of apoptotic cell–derived cholesterol within the engulfing phagocytes was the most likely mode by which ABCA1 upregulation occurred. Surprisingly, when we treated phagocytes with cytochalasin D, a blocker of actin polymerization that allows corpse binding but not internalization, the enhanced Abca1 upregulation was still observed (Figure 2A and Supplemental Figure 2A). In contrast, blocking transcription in phagocytes with actinomycin D strongly inhibited Abca1 induction by apoptotic cells, suggesting that apoptotic cells induce new transcription rather than a change in the rate of Abca1 message turnover (Figure 2A). This suggested that perhaps an event initiated at the membrane, independent of intracellular cholesterol sensing, might trigger Abca1 gene transcription. To test whether the cholesterol content of the apoptotic targets was important for the upregulation of Abca1, as has been previously shown, we treated apoptotic cells with methyl-β-cyclodextran (MJCD) to extract their membrane cholesterol before adding to phagocytes. Surprisingly, MJCD-treated apoptotic cells were still able to induce Abca1 upregulation, and any enhancement by MJCD was likely due to greater cell death among the treated cells (Figure 2B and Supplemental Figure 2B). As a third means of testing this possibility, we incubated the peritoneal macrophages with surrogate targets lacking sterols. These targets were carboxylate-modified beads that are thought to mimic certain negative charges characteristic of apoptotic cells and can compete with apoptotic cells for binding to phagocytes (31). These surrogate targets also induced Abca1 transcriptional upregulation, with this effect detectable in as little as 30 minutes (Figure 2C). The more rapid kinetics of Abca1 induction by the beads, compared with apoptotic cell induction, was likely due to the beads being more uniform in their charge expression, facilitating better binding to macrophages.

The Abca1 upregulation induced by apoptotic cells is independent of LXR. Liver X receptors (LXRs) are crucial regulators of sterol-dependent upregulation of ABCA1, and the binding of LXR to specific sites on the ABCA1 promoter has been well described (32, 33). It has also been reported that in thioglycollate-elicited macrophages, LXR-regulated messages (including Abca1) are upregulated at 24 hours after apoptotic cell engulfment (34, 35). In contrast, the rapid time frame of Abca1 upregulation in our system, the lack of a need for corpse internalization, and the dispensability of cholesterol in the targets suggested that apoptotic cell–initiated Abca1 upregulation might be independent of LXR (Figure 3A). To test this directly, we assessed the response of primary peritoneal...
Importantly, the LXR antagonist GSK-1440233A was unable to prevent apoptotic cell–induced upregulation of Abca1, but it was able to potently block Abca1 induction by the LXR agonist TO-901317 (Figure 3D). Furthermore, addition of the LXR antagonist did not alter the kinetics of Abca1 upregulation after apoptotic cell treatment (Supplemental Figure 3). Also, while Abca1 was upregulated by both apoptotic cells and LXR agonists, Abcg1 was only upregulated by TO-901317 (Figure 3E). These data suggest that apoptotic cell recognition utilizes an LXR-independent mechanism for upregulating Abca1.

To further explore the role of LXR in apoptotic cell–induced Abca1 upregulation, we assessed Abca1 levels in WT macrophages after treatment with agonists or antagonists of LXR (Figure 3A). Adding the LXR activator TO-901317 along with apoptotic cells had an additive effect on Abca1 transcript levels in macrophages (Figure 3D). Importantly, the LXR antagonist GSK-1440233A was unable to prevent apoptotic cell–induced upregulation of Abca1, but it was able to potently block Abca1 induction by the LXR agonist TO-901317 (Figure 3D). Furthermore, addition of the LXR antagonist did not alter the kinetics of Abca1 upregulation after apoptotic cell treatment (Supplemental Figure 3). Also, while Abca1 was upregulated by both apoptotic cells and LXR agonists, Abcg1 was only upregulated by TO-901317 (Figure 3E). These data suggest that apoptotic cell recognition utilizes an LXR-independent mechanism for upregulating Abca1. Collectively, these data suggest that the rapid ABCA1 induction in response to apoptotic cell recognition involves a membrane-initiated signaling pathway that functions independently of the LXR sterol–sensing mechanism.
The BAI1/ELMO1/Rac pathway is necessary for efficient upregulation of ABCA1 in response to apoptotic cells. Phagocytes engage ligands on apoptotic cells either directly or indirectly via multiple engulfment receptors. Two pieces of evidence led us to hypothesize that a direct PtdSer receptor might initiate the signaling event. First, carboxylate-modified beads, which lack most characteristics of apoptotic cells other than the negative charge due to PtdSer exposure, were sufficient to induce Abca1 upregulation. Second, these short-term assays for Abca1 upregulation were carried out in X-VIVO 10 medium (serum free and devoid of exogenous serum proteins known to bridge PtdSer on apoptotic cells to the certain engulfment receptors on phagocytes). BAI1 and TIM-4 are 2 engulfment receptors expressed on macrophages that directly engulf PtdSer on apoptotic cells, but are thought to signal by independent modalities. To test their relevance in Abca1 upregulation, we isolated resident peritoneal macrophages from mice lacking BAI1 (38) or TIM-4 (39) or from their littermate controls and incubated them with apoptotic cells (Figure 4A and Supplemental Figure 4, A and B). There was no noticeable difference in the number of recovered macrophages in either of the mouse genotypes, and basally, the morphology and growth properties of these macrophages were indistinguishable from control macrophages isolated in parallel from WT mice. While the loss of either BAI1 or TIM4 led to a partial defect in apoptotic cell engulfment, only the BAI1-deficient macrophages showed an attenuated upregulation of Abca1 (Figure 4, B–E), despite the known role of TIM-4 in corpse binding (40). These data suggest that Abca1 upregulation induced by apoptotic cells utilizes a pathway that, at least in part, depends on the PtdSer recognition receptor BAI1.

The signaling downstream of BAI1 occurs via an evolutionarily conserved module involving the cytoplasmic proteins ELMO and DOCK that act as a bipartite guanine nucleotide exchange factor (GEF) for the small GTPase Rac1, which then promotes corpse uptake (41, 42) (see schematic in Figure 4A). To test the relevance of these cytoplasmic proteins, we used mice that we previously generated, either globally lacking Elmo1 (43) or conditionally lacking Rac1 in macrophages (as Rac1 global deletion leads to embryonic lethality) (44) (Figure 4A and Supplemental Figure 4, C and D). Peritoneal macrophages from Elmo1−/− mice showed a significant reduction in ABCA1 upregulation in response to apoptotic cells compared with control littersates (Figure 4F). Similarly, loss of Rac1 expression in macrophages also significantly attenuated apoptotic cell–induced Abca1 upregulation compared with that of littersates (Figure 4H). As has been shown previously, the corpse internalization per se by Elmo1−/− macrophages was largely unaffected, due to functional compensation by ELMO2 in engulfment (43) (Figure 4G). Loss of Rac1 led to a strong decrease in apoptotic cell engulfment (Figure 4I). There was still residual Abca1 upregulation in these Rac1- and ELMO1-deficient macrophages, suggesting that other signals initiated by apoptotic cell recognition likely also contribute to Abca1 upregulation. This is not dissimilar to what is normally seen with engulfment, where elimination of single or multiple engulfment-related proteins does not completely eliminate the capacity of phagocytes to clear apoptotic cells due to partial redundancy among pathways. Collectively, these data using primary macrophages from mice lacking specific engulfment proteins identify the BAI1/ELMO/Rac signaling module as part of a membrane-initiated signaling pathway that drives Abca1 upregulation upon apoptotic cell recognition.

Loss of BAI1 affects corpse clearance and serum lipid levels in vivo. Since one of the primary functions of macrophages under homeostatic conditions involves removal of apoptotic cells and BAI1 seems to affect both cell clearance and ABCA1 upregulation, we next tested the loss of BAI1 in vivo. Mutations in ABCA1 were previously found to be causative for Tangier disease, and these patients have very low serum HDL levels and accumulate lipid-laden macrophages in tissues (45). Furthermore, in Tg mice, small changes in ABCA1 have been shown to systematically affect serum lipid levels (46). To test whether this BAI1-initiated Abca1 upregulation might be relevant in vivo, we placed the BAI1 KO mice on a high-fat Western diet to assess the development of dyslipidemia and atherosclerosis. Interestingly, the BAI1 null mice fed Western diet (assessed at 30 weeks) displayed a mild increase in the levels of TUNEL-positive apoptotic cells in aortic root sections compared with WT littersmates (Supplemental Figure 5A). However, when the serum lipids were assessed over 30 weeks, we did not see a significant change in serum lipids in the BAI1 KO mice (Supplemental Figure 5, B–G).

Since phenotypes due to genes linked to dyslipidemia are often better detected when the mice also lack LDL receptor (LDLR), with features that resemble certain aspects of the human disease (47), we crossed the BAI1 KO mice with Ldlr−/− (denoted Ldr KO) mice. Abca1 deletion in phagocytes on this background has yielded mixed results in atherosclerosis; bone marrow chimeras using Abca1−/− donors and Ldr KO recipients resulted in increased atherosclerotic plaque area and decreased serum lipids (48–50), whereas more recent studies using myeloid cell–specific ABCA1 deletion bred onto the LdrKO background resulted in little change in atherosclerosis, but significant decreases in serum lipids (51). We placed the BAI1−/−Ldlr−/− (denoted BAI1 KO/Ldr KO) mice on a Western diet for 15 weeks and assessed their phenotypes. We found an increased macrophage burden (as measured by Mac2 staining) within the plaques of the BAI1 KO/Ldr KO mice. However, despite the presence of more macrophages, the BAI1 KO/Ldr KO mice showed a greater number of uncleared apoptotic cells in atherosclerotic plaques formed in their aortic roots compared with their control littersmates (as measured by cleaved caspase 3 staining), suggesting a defect in corpse clearance within the plaques of mice lacking BAI1 (Figure 5, A and B). The BAI1 KO/Ldr KO mice also had significantly lower serum levels of total cholesterol, HDL, LDL, and triglycerides compared with the littermate Ldr KO mice (Figure 5C), but did not show a statistically significant difference in atherosclerotic lesions (Supplemental Figure 6, A–D). This phenotype of the BAI1 KO/Ldr KO null mice is remarkably similar to that observed with specific Abca1 deletion in macrophages (in the LDR-deficient background) (51). The latter mice also did not show a difference in atherosclerotic lesions compared with their littersmates, but did show a decrease in serum lipids (51), essentially similar to that observed here in the BAI1-null mice. These data suggest that the decrease in apoptotic cell–induced Abca1 upregulation seen with the loss of BAI1 could translate to dyslipidemia in vivo that is analogous to that seen in mice lacking ABCA1 specifically in macrophages.
Overexpression of BAI1 enhances ABCA1 expression in response to apoptotic cells. We next asked whether boosting the signaling via the BAI1-initiated signaling pathway can lead to higher ABCA1 upregulation in response to apoptotic cells and whether this can translate to a “gain of function” in vivo. We first tested this in vitro using LR73 cell lines overexpressing WT BAI1 or HA-tagged BAI1. Cells overexpressing BAI1 showed enhanced cholesterol efflux to ApoA1 when exposed to apoptotic cells compared with control LR73 cells (Figure 6A). To test this in primary macrophages, we used Tg mice that we recently engineered to globally
overexpress WT BAI1 (R26\textsuperscript{CTV-Bai1}, herein referred to as Tg BAI1) (C.S. Lee, unpublished observations) (Figure 6B and Supplemental Figure 4E). When we isolated peritoneal macrophages from the Tg BAI1 mice and incubated them with apoptotic cells, they showed enhanced engulfment compared with macrophages from non-Tg littermate mice (Figure 6D). When \textit{Abca1} upregulation was assessed, the peritoneal macrophages from the Tg BAI1 mice had enhanced \textit{Abca1} expression in response to apoptotic cells compared with control mice (Figure 6C).

To test whether this effect of BAI1 required downstream signaling via ELMO1, we used another line of Tg mice that we generated in parallel, where the mice overexpressed a mutant form of BAI1 (R26\textsuperscript{CTV-Bai1-AAA}, herein referred to as Tg BAI1-AAA) (C.S. Lee, unpublished observations). Although the BAI1-AAA protein gets expressed on the surface at levels comparable to that of the WT BAI1, due to the cytoplasmic point mutations, this BAI1-AAA fails to bind ELMO and link to ELMO/Rac-mediated downstream signaling. Macrophages overexpressing the BAI1-AAA did not show a detectable increase in \textit{Abca1} upregulation when incubated with apoptotic cells and had no increase in their engulfment capacity compared with littermate controls (Figure 6, C and D). These data further support the concept that BAI1-initiated signaling events can upregulate \textit{Abca1} and also highlight the importance of ELMO in mediating the signal downstream of BAI1.

We then crossed the WT Tg BAI1 mice onto the LDLR-deficient background and placed them on a Western diet to test whether gain of function in BAI1 signaling and \textit{Abca1} upregulation had an effect in vivo. Under these settings, while the overexpression of WT BAI1 per se did not reduce the number of apoptotic cells within the plaques or the size of the lesions, the Tg BAI1 Ldlr\textsuperscript{−/−} mice displayed higher ratios of HDL to total cholesterol and HDL to LDL (Figure 6E), suggesting an effect of Tg BAI1 expression on lipid homeostasis.

Discussion

Collectively, the data presented here suggest several important insights. First, this work identifies a plasma membrane-initiated pathway in phagocytes, driven by apoptotic cell recognition, that can lead to upregulation of ABCA1 and in turn regulate cholesterol homeostasis in vivo. Although ABCA1 is recognized as a critical
id homeostasis has not been addressed. The attenuation of ABCA1 upregulation due to loss of BAI1 translates to a greater number of uncleared apoptotic cells in the aortic roots; it also correlated with altered lipid levels in vivo. Conversely, enhancing the signaling via BAI1 (in Tg mice) improves the HDL/LDL ratio, suggesting a beneficial effect of this signaling. HDL, in addition to its role in getting rid of excess cholesterol through reverse cholesterol transport, has also been linked to antiinflammatory effects in different tissues and contexts. Therefore, in addition to the known antiinflammatory mediators elicited in macrophages by apoptotic cell recognition (such as TGF-β, IL-10, and PGE2) (9), the ABCA1-dependent generation of HDL may provide additional antiinflammatory benefits.

Third, there is extensive correlation in humans of higher HDL levels with lower cardiovascular disease, which forms the basis for attempts to increase HDL levels in patients to provide a benefit against cardiovascular disease; however, recent efforts to increase HDL levels have not yielded a benefit (53). This may be

**Figure 6. BAI1 signaling affects serum lipid levels in dyslipidemic Ldlr-deficient mice.** (A) Control LR73 (gray), BAI1-overexpressing LR73 (dark blue), or HA-tagged BAI1-overexpressing (HA-BAI1) LR73 (light blue) cells were treated with apoptotic Jurkat cells and their efflux 3H-cholesterol to ApoA1 was assessed (mean ± SD). Representative of 3 independent experiments. (B) Schematic for the generation of Tg mice overexpressing BAI1. The Tg constructs engineered to express WT BAI1 and BAI1-AAA mutant (that fail to engage ELM01-mediated downstream signaling) contain a loxP-flanked STOP cassette preceding the coding sequence for BAI1. These constructs were knocked into the Rosa26 locus of C57BL/6 ES cells, from which Tg mice were generated. Upon crossing with E2A-Cre–expressing mice and Cre-mediated removal of the STOP cassette, BAI1 and BAI1-AAA expression were attained. (C) Peritoneal macrophages from Tg BAI1 or Tg BAI1-AAA mice were incubated with apoptotic Jurkat cells. Abca1 upregulation (compared with untreated controls) was measured, and data are shown as normalised to littermate controls (WT) (mean ± SEM). *P < 0.05 (t test). (D) Representative assay of at least 2 independent experiments for the engulfment of apoptotic thymocytes by peritoneal macrophages isolated from Tg BAI1 or Tg BAI1-AAA mice (mean ± SD). Combined Tg BAI1 (n = 9–10 mice) and Tg BAI1-AAA (n = 6–7 mice) statistics are shown. *P < 0.05, P = 0.887 for BAI1-AAA vs. WT (t test). (E) Tg BAI1 Ldlr–/– mice were fed a Western diet for 15 weeks, and the ratios of HDL/total cholesterol and HDL/LDL in the serum were analyzed. *P < 0.05 (t test).
due in part to the initial emphasis placed on raising HDL levels in isolation and/or HDL being raised via pharmacological or supraphysiological mechanisms (53). Similarly, LXR agonist drugs have also faced problems with toxicity issues, likely due to the “sledgehammer” nature of this approach, with many LXR target genes being simultaneously activated or inhibited (54). The cell clearance-initiated pathway identified here leads to ABCA1 expression (and in turn HDL levels), which occurs routinely in many tissues as part of normal homeostasis and may provide a safer alternative. It is possible that targeting the LXR-independent BAI1/ELMO1/Rac1 pathway at the membrane (either by directly activating BAI1 or perhaps with liposomes mimicking features of apoptotic cells) might be of benefit by triggering a natural cellular pathway with less adverse effects.

Methods
Mice. C57BL/6 mice were obtained from Jackson Laboratories. Lxra/b+/– mice were provided by David Mangelsdorf (University of Texas Southwestern Medical Center, Dallas, Texas, USA) (55). We have previously reported the generation of Bait1–/– mice (38) and Elm1–/– mice (43). Tima+/– mice were provided by Vijay Kuchroo (Harvard Medical School, Boston, Massachusetts, USA) (39). To conditionally delete Rac1 in the myeloid lineage, we crossed Rac1fl/fl mice (56) with Lysm-Cre to generate Rac1fl/+ Lysm-Cre mice (44). Tg Bait1 mice were generated by engineering either the WT BAIT or the BAIT-AAA mutant coding sequences within the CTV vector and knocking them into the Rosa26 locus of C57BL/6 embryonic stem (ES) cells. The ES cells were then used to generate the Tg mice. The fidelity of the STOP cassette and the expression of BAI1 or BAI1-AAA mutants after crossing to E2A mice were confirmed by PCR and protein expression (38). Bait1–/– mice were bred to Ldlr–/– mice (on a C57BL/6 background) to obtain Bait1–/– Ldlr–/– mice and the control Bait1+/– Ldlr–/– mice (43). To conditionally delete Rac1 in the myeloid lineage, we crossed Rac1fl/fl mice (56) with Lysm-Cre to generate Rac1fl/+ Lysm-Cre mice (44). Tg Bait1 mice were generated by engineering either the WT BAIT or the BAIT-AAA mutant coding sequences within the CTV vector and knocking them into the Rosa26 locus of C57BL/6 embryonic stem (ES) cells. The ES cells were then used to generate the Tg mice. The fidelity of the STOP cassette and the expression of BAI1 or BAI1-AAA mutants after crossing to E2A mice were confirmed by PCR and protein expression (38). Bait1–/– mice were bred to Ldlr–/– mice (on a C57BL/6 background) to obtain Bait1–/– Ldlr–/– mice, which were then crossed to produce cohorts of Bait1–/– Ldlr–/– mice (denoted Bait1–/– Ldlr–/–) and the control Bait1+/– Ldlr–/– mice (denoted Ldlr–/–). Female mice were used in these experiments.

Quantitative RT-PCR. Total RNA was isolated from cells using the Quick RNA MiniPrep Kit (Zymo Research), and cDNA was generated using the QuantiTect Reverse Transcriptase Kit (QiAGEN) according to the manufacturer’s instructions. Gene expression for mouse Abca1 normalized to Hprt was measured using TaqMan probes (Applied Biosystems) by Real-Time PCR with a StepOnePlus qPCR system (Applied Biosystems).

Analysis of Abca1 upregulation in vivo. For RNA measurements, 80 million human Jurkat T cells (from ATCC, clone E6-1) in 4 ml of X-VIVO 10 (Lonza) were UV irradiated and incubated for 4 hours to induce apoptosis. 300 μg of apoptotic cells (6 million cells) or X-VIVO 10 alone were injected intraperitoneally per mouse, with 8 mice per treatment condition. After 4 hours, the mice were euthanized, the peritoneum was lavaged with 10 ml PBS plus 5% FBS, and cells collected were lysed for RNA isolation. For cell-surface ABCA1 expression, 250 μg of X-VIVO 10 or X-VIVO 10 containing 10 million unstained apoptotic thymocytes (prepared as described below) were intraperitoneally injected into WT female mice. After 6 hours, mice were euthanized and peritoneal cells were collected as described above and stained for CD11b (eBioscience, 17-0112-82), IgM (Life Technologies, A21042), Ly6G (eBioscience, 35-5931-81), and ABCA1 (as described below). Flow cytometry was performed using a FACSCanto (BD Biosciences) and the data analyzed using FlowJo software (TreeStar Inc.).
Aortic root analysis. 


